Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 12:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Thrombotic Disorder Clear all
Completed Early Phase 1 Interventional

Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic Purpura

NCT00486421
View directory record Official record
Conditions
Nonneoplastic Condition
Interventions
Rituximab, Prednisone
Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Jun 26, 2026, 12:37 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

NCT04596995
View directory record Official record
Conditions
Primary Immune Thrombocytopenia
Interventions
Rozanolixizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 4, 2024 · Synced Jun 26, 2026, 12:37 AM EDT
Completed No phase listed Observational

HTRS TE Registry (ThromboEmbolism Registry)

NCT00266994
View directory record Official record
Conditions
Thromboembolism
Interventions
Not listed
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Not listed
Enrollment
2,760 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Jun 26, 2026, 12:37 AM EDT
Recruiting Phase 3 Interventional

Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease

NCT07318610
View directory record Official record
Conditions
Peripheral Artery Disease (PAD)
Interventions
REGN7508, REGN9933, Placebo, Rivaroxaban
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
7,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Crystal River, Florida • Amarillo, Texas • DeSoto, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jun 26, 2026, 12:37 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab

NCT01471691
View directory record Official record
Conditions
Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Macular Edema
Interventions
ranibizumab 0.5mg, ranibizumab 1.0mg
Drug
Lead sponsor
Hanscom, Thomas, M.D.
Individual
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
4
States / cities
Huntington Beach, California • Long Beach, California • Santa Monica, California + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Jun 26, 2026, 12:37 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion

NCT00168324
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
700 µg Dexamethasone, 350 µg Dexamethasone, Sham Injection
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Jun 26, 2026, 12:37 AM EDT
Completed Phase 2 Interventional

Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)

NCT00088283
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
pegaptanib sodium
Drug
Lead sponsor
Eyetech Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
35
States / cities
Tucson, Arizona • Los Angeles, California • Santa Ana, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2007 · Synced Jun 26, 2026, 12:37 AM EDT
Completed No phase listed Observational

The SCRIPPS DES REAL WORLD Registry

NCT00714623
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Restenosis, Coronary Thrombosis
Interventions
Sirolimus-Eluting Bx Velocity Coronary Stent (CypherTM Sirolimus-Eluting Stent)
Device
Lead sponsor
Paul S Teirstein, MD
Other
Eligibility
18 Years and older
Enrollment
859 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 23, 2012 · Synced Jun 26, 2026, 12:37 AM EDT
Recruiting Not applicable Interventional

Assessment of TRanscathetEr and Surgical Aortic BiOprosthetic Valve Thrombosis and Its TrEatment With Anticoagulation

NCT02318342
View directory record Official record
Conditions
Prosthetic Valve Thrombosis
Interventions
Warfarin
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jun 26, 2026, 12:37 AM EDT
Withdrawn No phase listed Observational

Single Center Post-Market Study of Thrombolytic Therapy Using the Versus™ Catheter

NCT06975969
View directory record Official record
Conditions
Blood Clots, Vascular Disease, Embolism Thrombosis, Cardiovascular Diseases, Lung Diseases
Interventions
Versus™ Endovascular Pulmonary Artery Drug Delivery Catheter
Device
Lead sponsor
Liquet Medical Inc.
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jun 26, 2026, 12:37 AM EDT
Completed Not applicable Interventional Results available

Apollo Device for Fatigue in Systemic Sclerosis

NCT04854850
View directory record Official record
Conditions
Systemic Sclerosis, Fatigue, Raynaud Phenomenon
Interventions
Apollo
Device
Lead sponsor
Robyn T. Domsic, MD, MPH
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Jun 26, 2026, 12:37 AM EDT
Completed Not applicable Interventional

A Prospective Study to Determine the Effectiveness of Reaming in Reducing Fat Emboli to the Lungs

NCT00327158
View directory record Official record
Conditions
Diaphyseal Femur Fracture
Interventions
Transesophageal transducer, echocardiography
Procedure
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 27, 2010 · Synced Jun 26, 2026, 12:37 AM EDT
Recruiting No phase listed Observational

Cleaner Long-tErm Assessment Registry - Venous Insights and Efficacy With eXtended Tracking

NCT07102160
View directory record Official record
Conditions
Deep Vein Thrombosis (DVT), Thrombus in the Peripheral Venous Vasculature, Venous Embolism, Thrombus in the Central and Peripheral Circulatory System, Including Saphenous Vein Grafts
Interventions
Aspiration thrombectomy system
Device
Lead sponsor
Argon Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Fort Lauderdale, Florida • Tampa, Florida • Edgewood, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jun 26, 2026, 12:37 AM EDT
Recruiting Phase 3 Interventional

REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants

NCT07213778
View directory record Official record
Conditions
Symptomatic Venous Thromboembolism (VTE)
Interventions
REGN7508, Acetylsalicylic Acid (ASA), Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
23
States / cities
Rancho Mirage, California • Lone Tree, Colorado • Miami, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jun 26, 2026, 12:37 AM EDT
Completed Not applicable Interventional Results available

The SENTRY Clinical Study

NCT01975090
View directory record Official record
Conditions
Pulmonary Embolism, Deep Vein Thrombosis
Interventions
SENTRY IVC Filter
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
20
States / cities
Birmingham, Alabama • Palo Alto, California • Colorado Springs, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2021 · Synced Jun 26, 2026, 12:37 AM EDT
Terminated Phase 4 Interventional Results available

Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism

NCT04558125
View directory record Official record
Conditions
Pulmonary Embolism, COVID
Interventions
TNKase, Placebo, Enoxaparin
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Jun 26, 2026, 12:37 AM EDT
Terminated Phase 1 Interventional

Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD, DME and RVO

NCT03790852
View directory record Official record
Conditions
Wet Age-related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
KSI-301
Drug
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
21 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
11
States / cities
Phoenix, Arizona • Beverly Hills, California • Mountain View, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Jun 26, 2026, 12:37 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer

NCT00320255
View directory record Official record
Conditions
Thrombosis, Cancer, Pulmonary Embolism
Interventions
Apixaban, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 90 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
8
States / cities
Tucson, Arizona • Los Angeles, California • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2016 · Synced Jun 26, 2026, 12:37 AM EDT
Completed No phase listed Observational

Echo Detection of Endoscopic Retrograde Cholangiopancreatography (ERCP) Air Embolus

NCT01535248
View directory record Official record
Conditions
Air Embolism as A Complication of Medical Care
Interventions
Transthoracic Echocardiography
Other
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Jun 26, 2026, 12:37 AM EDT
Completed Phase 3 Interventional

Steroid Injections vs. Standard Treatment for Macular Edema Due to Retinal Blood Vessel Blockage

NCT00106132
View directory record Official record
Conditions
Retinal Vein Occlusion, Macular Edema, Cystoid, Macular Edema
Interventions
Triamcinolone Acetonide
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
1,260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 26, 2026, 12:37 AM EDT
Completed Not applicable Interventional

The Effect of Tranexamic Acid on Blood Coagulation in Total Hip Arthroplasty Surgery

NCT03897621
View directory record Official record
Conditions
Coagulation; Intravascular, Rotational Thromboelastometry, Fibrinolysis; Hemorrhage, Tranexamic Acid, Total Hip Arthroplasty
Interventions
Tranexamic Acid, Placebo
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Jun 26, 2026, 12:37 AM EDT
Recruiting Not applicable Interventional

Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease

NCT07613840
View directory record Official record
Conditions
Peripheral Arterial Disease (PAD), Amputation, Thrombosis, Thrombosis (Stent Thrombosis), Platelet Aggregation Inhibitors, Thromboelastography (TEG), PRU(Platelet Reactivity Unit)
Interventions
Aspirin, Clopidogrel, Ticagrelor, Rivaroxaban, Thromboelastography with Platelet Mapping
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • Salem, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jun 26, 2026, 12:37 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions

NCT00407355
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
Intravitreal injection of ranibizumab .3 dose, Intravitreal injection of Ranibizumab .5 dose
Drug
Lead sponsor
Peter A Campochiaro, MD
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Jun 26, 2026, 12:37 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Heart Disease Risk Factors in Major Depression

NCT00001969
View directory record Official record
Conditions
Adrenal Gland Hyperfunction, Cardiovascular Disease, Involutional Depression
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
21 Years to 55 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jun 26, 2026, 12:37 AM EDT